Press releases
- AbCellera Reports Q1 2024 Business Results
- AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
- AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
- AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
- AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
- AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
- AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
- AbCellera Announces Resignation of Board Member
- AbCellera to Present at Upcoming Investor Conferences in March
- AbCellera Reports Full Year 2023 Business Results
More ▼
Key statistics
On Friday, Abcellera Biologics Inc (8QQ:DUS) closed at 3.57, 6.21% above its 52-week low of 3.36, set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.65 |
---|---|
High | 3.65 |
Low | 3.57 |
Bid | 3.53 |
Offer | 3.58 |
Previous close | 3.66 |
Average volume | 15.56 |
---|---|
Shares outstanding | 293.92m |
Free float | 211.51m |
P/E (TTM) | -- |
Market cap | 1.16bn USD |
EPS (TTM) | -0.5056 USD |
Data delayed at least 15 minutes, as of May 10 2024 18:32 BST.
More ▼